DS
ADMA icon

David Shaw’s ADMA Biologics ADMA Stock Holding History

David Shaw’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1M Buy
5,274,597
+4,713,770
+841% +$43M 0.02% 820
2026
Q1 		$5.05M Buy
560,827
+3,674
+0.7% +$58K ﹤0.01% 2166
2025
Q4 		$10.2M Buy
557,153
+224,452
+67% +$3.78M 0.01% 1738
2025
Q3 		$4.88M Sell
332,701
-499,862
-60% -$8.57M ﹤0.01% 2226
2025
Q2 		$15.2M Sell
832,563
-692,964
-45% -$14.1M 0.01% 1212
2025
Q1 		$30.3M Sell
1,525,527
-1,541,048
-50% -$26.7M 0.03% 718
2024
Q4 		$52.6M Sell
3,066,575
-2,197,520
-42% -$41.3M 0.04% 555
2024
Q3 		$105M Sell
5,264,095
-1,560,422
-23% -$24.3M 0.09% 260
2024
Q2 		$76.3M Buy
6,824,517
+1,442,799
+27% +$12.1M 0.07% 331
2024
Q1 		$35.5M Sell
5,381,718
-1,131,835
-17% -$6.19M 0.03% 617
2023
Q4 		$29.4M Sell
6,513,553
-1,058,140
-14% -$3.91M 0.03% 707
2023
Q3 		$27.1M Sell
7,571,693
-602,124
-7% -$2.32M 0.03% 691
2023
Q2 		$30.2M Sell
8,173,817
-37,756
-0.5% -$140K 0.03% 644
2023
Q1 		$27.2M Sell
8,211,573
-296,836
-3% -$1.03M 0.03% 714
2022
Q4 		$33M Buy
8,508,409
+2,664,613
+46% +$8.22M 0.04% 622
2022
Q3 		$14.2M Buy
5,843,796
+1,011,404
+21% +$2.43M 0.02% 1083
2022
Q2 		$9.57M Buy
4,832,392
+2,930,104
+154% +$5.76M 0.01% 1421
2022
Q1 		$3.48M Buy
1,902,288
+1,812,981
+2,030% +$2.83M ﹤0.01% 2732
2021
Q4 		$126K Buy
+89,307
New +$117K ﹤0.01% 5012
2021
Q3 		– Sell
-211,692
Closed -$339K – 4926
2021
Q2 		$339K Buy
+211,692
New +$372K ﹤0.01% 4214
2020
Q4 		– Sell
-10,030
Closed -$24K – 3873
2020
Q3 		$24K Buy
+10,030
New +$27.5K ﹤0.01% 3768

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's ADMA Position: Q2 2026 in Review

David Shaw increased its ADMA Biologics (ADMA) stake by 841% in Q2 2026, buying an estimated $43M and bringing the position to 5,274,597 shares worth $44.1M. The position accounts for 0.02% of the portfolio, ranked #820.

David Shaw first reported a position in ADMA in Q3 2020 and has held it in 21 quarters since. The position peaked at $105M in Q3 2024. 321 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • David Shaw held 5,274,597 shares of ADMA Biologics worth $44.1M as of Q2 2026.
  • David Shaw bought 4,713,770 ADMA Biologics shares in Q2 2026, an estimated $43M.
  • ADMA Biologics made up 0.02% of David Shaw's portfolio in Q2 2026, its #820 holding.
  • David Shaw first reported a position in ADMA Biologics in Q3 2020 and has held it in 21 quarters since.
  • David Shaw's ADMA Biologics position peaked at $105M in Q3 2024.
  • 321 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.